Logo
x

Search category

Subscribe Now

ALK-Positive Metastatic NSCLC

Pfizer's Lorbrena (lorlatinib) Receives FDA Approval for Patients with 1L ALK- Positive Metastatic NSCLC

Pfizer's Lorbrena (lorlatinib) Receives FDA Approval for Patients with 1L ALK- Positive Metastatic NSCLC

  • November 20, 2018
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.